Ocular Therapeutix™ to Present at the Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019
Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference
November 14, 2019
Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update
November 12, 2019
Ocular Therapeutix Announces Strategic Update and Operational Restructuring
November 08, 2019
Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results
November 05, 2019
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2019
Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019
October 01, 2019
Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference
September 26, 2019
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis
September 24, 2019
Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference
August 29, 2019
Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
August 07, 2019
Ocular Therapeutix™ To Report Second Quarter 2019 Financial Results
August 01, 2019
Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
July 26, 2019
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2019
Ocular Therapeutix™ Announces Christopher White as Senior Vice President, Head of Business and Corporate Development
July 11, 2019
Ocular Therapeutix™ Announces Patricia Kitchen as Chief Operations Officer
July 09, 2019
Ocular Therapeutix™ Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States
July 01, 2019
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
June 21, 2019
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
May 30, 2019
Ocular Therapeutix™ Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA®
May 29, 2019
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma
May 20, 2019
Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update
May 10, 2019
Ocular Therapeutix™ To Report First Quarter 2019 Financial Results
May 02, 2019
Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS
May 01, 2019
Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc.
April 30, 2019
Ocular Therapeutix™ to Present New Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
April 24, 2019
Ocular Therapeutix™ Reports Changes to Board of Directors
April 23, 2019
Ocular Therapeutix™ to Present at the H.C. Wainwright Global Life Sciences Conference
April 03, 2019
Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
April 02, 2019
Ocular Therapeutix™ Reports Election of Leslie Williams to Board of Directors
March 25, 2019
Ocular Therapeutix™ to Host 2019 Research & Development Day
March 21, 2019
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update
March 07, 2019
Ocular Therapeutix™ to Present at the Cowen and Company 39th Annual Health Care Conference
March 05, 2019
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2018 Financial Results
March 01, 2019
Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing
February 21, 2019
Ocular Therapeutix™ Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD)
February 20, 2019
Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
January 10, 2019
Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain
January 07, 2019
